Hodgkin's Lymphoma Perspective

 
 
  • Finding the Patient With Primary Biliary Cirrhosis If you don't consider it, you might miss the diagnosis of this slowly progressive autoimmune disorder.
  • What's the Medical History?   Dr Ronald Wharton asks you to identify the patient's medical history from these echocardiography images.
  • The Future of Hodgkin Lymphoma -- Brentuximab and Beyond   Dr Bruce Cheson and Dr Ann LaCasce highlight data from ASH 2014 on brentuximab vedotin and discuss promising agents for Hodgkin lymphoma, including checkpoint inhibitors nivolumab and pembrolizumab.
  • Double-Hit Lymphomas Explained, With Surprising EPOCH-R Data   Dr Bruce Cheson and Dr Andrew Zelenetz define 'double-hit' lymphomas and discuss trial results for these hard-to-treat patients, as well as other promising agents in lymphoma.
  • Eponyms From A to Z In medicine, there are thousands of diseases, tests, and conditions named for their discoverer. How many can you recognize?
  • ASH 2014: If You're Going to San Francisco…   Dr Bruce Cheson previews important data being presented at the upcoming ASH 2014 meeting, including studies of CLL, Hodgkin lymphoma, and the role of interim PET scans in large cell lymphoma.
  • What's New: Imaging in Lymphoma   Dr Bruce Cheson breaks down new consensus recommendations on the role of imaging in staging and response assessment for lymphoma.
  • Cancer Rates in Kids: Looking Behind the Numbers A recent study examined rates and trends in childhood cancers. Medscape spoke with the lead researcher.
  • ASCO President on the Triumph of the Open Mind   Dr. James Holland, president of ASCO in 1976-1977, talks to Dr. Kathy Miller about the early days of oncology, the society, and the humanist passion that is a driving force for both.
  • Quiz: Historic Moments in Cancer Care How much do you know about the history of cancer care?
  • ASCO® 2014: Aiming at Cancer’s Achilles Heel   Four leading oncologists discuss the top studies from ASCO 2014 and how immunotherapy is reshaping cancer care and practice.
  • What to Watch in Lymphoma, Leukemia   Dr. Bruce Cheson reviews a wealth of practice-changing and practice-confirming studies from the lymphoma and leukemia sessions at ASCO 2014.
  • Abandoning PETs in Lymphoma   Drs. Bruce Cheson and Gilles Salles discuss lymphoma highlights from ASCO 2013 on new targeted agents, potential combinations, and indications that surveillance requires few scans.
  • Lugano: Destination Lymphoma   Dr. Bruce Cheson previews important studies to be presented at the International Conference on Malignant Lymphoma, the preeminent forum on lymphoma, to be held in Lugano, Switzerland, in June 2013.
  • BTK Inhibitors Open Door to Lymphoma Cure   Dr. Bruce Cheson reports on a plethora of data presented at ASH 2012 that heralds what he considers a new era in lymphoma management, one in which a cure may be in sight.
  • Limit Therapy to Cure Limited-Stage HL?   Dr. John Radford discusses the RAPID trial, which suggests that PET scans may identify early-stage Hodgkin lymphoma patients who can be cured by chemotherapy alone, without radiotherapy.
  • Progress in Cancer Genomic Medicine: A Year in Review, 2012 Dr. Maurie Markman looks back at key research studies from 2012 and discusses how they affect our understanding of the role of cancer genomics in clinical practice.
  • ASH 2012: More Fuel for the Fire   Dr. Bruce Cheson highlights studies that should prove controversial and practice-changing, as well as new drugs that expand treatment options.
  • A Challenger to Interim PET in Lymphoma   Dr. Bruce Cheson reports on recent data suggesting that measurement of metabolic tumor volume and total lesion glycolysis may be a better predictor of outcome in lymphoma than interim PET scanning.
  • Why the Holdup on New Combo Therapies in Lymphoma?   Clinical trials to test combinations of therapies in Hodgkin lymphoma have hit bureaucratic bottlenecks, much to the frustration of Dr. Bruce Cheson.